Media
Long Shortz with Racura: Tackling MYC-driven cancer pathways
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) Executive Chair Dr Pete Smith to discuss the company’s HARNESS-1 lung cancer trial. Watch the video here
Racura teams with Purdue Uni to advance cancer drug candidate
Racura and Purdue University in US partner for molecular level studies on how (E,E)-bisantrene binds to the MYC-G4 DNA structure. Read the full article here.
Long Shortz with Racura: Lung cancer trial edges closer to patient enrolment
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) CEO Dr Daniel Tillett to discuss the company’s upcoming HARNESS-1 lung cancer trial. Watch the video here.
Pioneering Aussie biotechs pass the clinical test
The performance of the ASX life sciences sector during the reporting season is a precautionary tale about not trusting statistics – or at least not relying on them at face value. Read article here
Racura scientists develop cardioprotection blood test to support key trial
Racura Oncology scientists have developed a novel blood-based molecular test designed to assess the cardioprotective effects of its lead drug candidate RC220. Read article here.
Long Shortz with Racura: Unlocking major IP and clinical milestones in transformative quarter
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) executive director Peter Smith who talks through the company’s transformative quarter, marked by major intellectual property, clinical and funding milestones. Watch the interview here.
Proactive Investors: Race Oncology funds HARNESS-1 lung cancer trial
Race Oncology Ltd executive director and chairman Dr Peter Smith talked with Proactive about securing more than A$3.22 million via a private placement to fund the HARNESS-1 Phase 1a/b clinical trial. Read full article here.
Stockhead: Racura Oncology gains ethics approval for HARNESS-1 lung cancer trial
Special Report: Racura Oncology has taken a significant step forward in the clinical development of its next-generation cancer therapy RC220, receiving human ethics approval for a HARNESS-1 Phase 1a/b trial in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Read full article here.
The Australian: Racura Oncology targets two new cancer markets with RC220’s unique molecular action
Special Report: Racura Oncology has discovered the unique molecular mechanism of action for its RC220 therapy, opening two new major potential indications to explore in a clinical setting. Read full article here.
